Rivaroxaban NOBEL vascular 2.5 mg
Rivaroxaban NOBEL vascular 2.5 mg is a medicine authorised by Swissmedic under authorisation number 68021. The authorisation holder is NOBEL Pharma Schweiz AG. The medicinal product code is Synthetic medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 05 May 2022 and the authorisation is limited until 04 May 2027. ATC code B01AF01 places the medicine in the group Antithrombotic agents.
| Authorisation number | 68021 |
|---|---|
| Name | Rivaroxaban NOBEL vascular 2.5 mg |
| Full name | Rivaroxaban NOBEL vascular 2.5 mg, Filmtabletten |
| Authorisation holder | NOBEL Pharma Schweiz AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | B · Prescription only |
| ATC code | B01AF01 |
| First authorisation | 05 May 2022 |
| Authorisation validity | 04 May 2027 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Rivaroxaban NOBEL vascular 2.5 mg, Filmtabletten | B | 05 May 2022 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 56 | Tablette(n) | B01AF01 | 06.03.0. | B |
| 2 | 2 x 98 | Tablette(n) | B01AF01 | 06.03.0. | B |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Rivaroxaban NOBEL vascular 2.5 mg authorised in Switzerland?
Yes. Rivaroxaban NOBEL vascular 2.5 mg is authorised by Swissmedic under authorisation number 68021, data as of 01 September 2026. The authorisation is limited until 04 May 2027.
Which dispensing category does Rivaroxaban NOBEL vascular 2.5 mg have?
Rivaroxaban NOBEL vascular 2.5 mg is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Rivaroxaban NOBEL vascular 2.5 mg?
The authorisation holder is NOBEL Pharma Schweiz AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.